Avanir Pharmaceuticals, Inc. has filed an IND application with the FDA to begin a large Phase II trial of AVP-923, an investigational drug for the treatment of central neuropathic pain in patients with multiple sclerosis (MS). The study will evaluate the safety, tolerability, and efficacy of three dose levels of AVP-923 capsules for the treatment of central neuropathic pain in MS patients. AVP-923 is a combination of dextromethorphan (DM) and quinidine (Q). The trial is a multicenter, random...